Regenerative Medicine
Advanced injection therapy for knee osteoarthritis relief.
Available at these clinics:
Mississauga
Oakville
Advanced, ultrasound-guided injection therapy for knee osteoarthritis relief.
At MedCAiRE Health, we offer nSTRIDE® APS (Autologous Protein Solution), a cutting-edge, blood-derived injection designed to help reduce knee osteoarthritis pain by targeting inflammation at its biological source. Using on-site processing and real-time ultrasound guidance, nSTRIDE delivers a concentrated solution from your own blood directly into the knee joint.
nSTRIDE is an autologous biologic therapy that concentrates anti-inflammatory proteins and growth factors from your own blood, then injects that solution into the knee joint under ultrasound guidance for accuracy.
Your nSTRIDE APS solution may include:
nSTRIDE is not a steroid and not a lubricant. It is a biologically targeted option aimed at interrupting the inflammatory cascade involved in cartilage deterioration.
At MedCAiRE, nSTRIDE injections are performed under ultrasound guidance to support:
When helpful, X-ray imaging can also be used to confirm osteoarthritis severity and joint anatomy prior to treatment.
nSTRIDE is designed to support:
You may be a good fit if you:
Not sure if you qualify? We confirm this during your assessment and imaging review.
We start with a focused knee history and exam, followed by review of any diagnostics to assess joint structure and osteoarthritis severity.
If needed, we may recommend further X-rays/ultrasound/MRI to confirm the stage and alignment factors that affect outcomes.
1) Blood draw
A small blood sample is taken from your arm.
2) On-Site Processing
Your blood is processed on-site to prepare the APS solution.
3) Ultrasound-Guided Injection
The APS solution is injected precisely into the knee joint under ultrasound guidance.
Most clients return to light activity within 24–48 hours. A personalized rehab plan may be provided based on your goals, symptoms, and exam findings.
Most patients tolerate the procedure well. Local anesthetic may be used, and ultrasound guidance supports comfort and precision.
nSTRIDE is designed as a single-injection treatment, but some patients may benefit from re-evaluation if symptoms return (often around the 12-month mark).
nSTRIDE is not covered by OHIP. Some extended health plans may reimburse a portion depending on your plan.
APS has been studied for early to moderate knee OA and has shown symptom improvement with a favorable safety profile in published clinical research.
